Literature DB >> 9619690

Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.

L M Koran1, S Pallanti, R S Paiva, L Quercioli.   

Abstract

OBJECTIVE: We compared gradually increased to pulse loaded doses of open-label, intravenous clomipramine (CMI) in patients with obsessive-compulsive disorder (OCD).
METHOD: We treated adult outpatients with DSM-III-R OCD, who had no prior exposure to effective treatments. Pulse loading patients received 150 mg on day 1; 150 mg or 200 mg on day 2. Gradual dosing patients received 25 mg per day increased to 200 mg per day over 2 weeks and then continued for a mean of 43 days (n=40). After i.v. dosing, all patients received oral CMI; the total treatment period was 6 months.
RESULTS: Pulse loading completers (n=7) had a rapid, dramatic response (mean Y-BOCS score decrease of 32% five days after pulse-loading). At this point (day 7), completers in the gradual intravenous group (n=20) exhibited no mean change in Y-BOCS score. The pulse loading group reached both a 25% or greater and a 50% or greater decrease in Y-BOCS score statistically and clinically significantly faster than the gradual group.
CONCLUSIONS: Pulse-loaded intravenous CMI for the treatment of OCD deserves further study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619690     DOI: 10.1016/s0924-977x(97)00048-5

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

Review 1.  Pharmacological management of treatment-resistant obsessive-compulsive disorder.

Authors:  Anat Abudy; Alzbeta Juven-Wetzler; Joseph Zohar
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

Review 2.  Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.

Authors:  L D Kochan; A I Qureshi; B A Fallon
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 3.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04

4.  Management of obsessive-compulsive disorder with fluvoxamine extended release.

Authors:  Lídia Ordacgi; Mauro V Mendlowicz; Leonardo F Fontenelle
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

5.  Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Wael Karameh Karameh; Munir Khani
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-28       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.